Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 8,582,419 shares, a growth of 22.3% from the February 15th total of 7,016,497 shares. Based on an average daily volume of 3,685,729 shares, the short-interest ratio is presently 2.3 days. Approximately 7.5% of the company’s shares are short sold.
Shares of Achillion Pharmaceuticals (NASDAQ:ACHN) opened at $4.23 on Friday. The company has a market capitalization of $615.13, a PE ratio of -6.82 and a beta of 1.03. Achillion Pharmaceuticals has a twelve month low of $2.58 and a twelve month high of $5.66.
Achillion Pharmaceuticals (NASDAQ:ACHN) last announced its earnings results on Thursday, February 22nd. The biopharmaceutical company reported ($0.17) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.01). During the same quarter last year, the firm posted ($0.03) earnings per share. analysts expect that Achillion Pharmaceuticals will post -0.55 EPS for the current year.
Several large investors have recently made changes to their positions in ACHN. Teacher Retirement System of Texas purchased a new stake in shares of Achillion Pharmaceuticals during the 4th quarter valued at about $109,000. Bourgeon Capital Management LLC raised its holdings in shares of Achillion Pharmaceuticals by 64.4% during the 4th quarter. Bourgeon Capital Management LLC now owns 48,504 shares of the biopharmaceutical company’s stock valued at $140,000 after buying an additional 19,004 shares during the period. MetLife Investment Advisors LLC purchased a new stake in shares of Achillion Pharmaceuticals during the 4th quarter valued at about $162,000. SG Americas Securities LLC raised its holdings in shares of Achillion Pharmaceuticals by 59.8% during the 3rd quarter. SG Americas Securities LLC now owns 42,229 shares of the biopharmaceutical company’s stock valued at $190,000 after buying an additional 15,800 shares during the period. Finally, BlueCrest Capital Management Ltd purchased a new stake in shares of Achillion Pharmaceuticals during the 4th quarter valued at about $209,000. Institutional investors and hedge funds own 81.42% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.tickerreport.com/banking-finance/3254377/achillion-pharmaceuticals-inc-achn-short-interest-update.html.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery and development of small molecule drug therapies for infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the alternative pathway of the complement system.
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.